Ignite Creation Date:
2024-07-17 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06469957
Status:
RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-03
Brief Title:
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer
Sponsor:
Centre Hospitalier Régional dOrléans
Organization:
Centre Hospitalier Régional dOrléans
Study Overview
Official Title:
Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer Treated by Chemotherapy andor Immunotherapy or Oral Targeted Therapy
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
IMPACTO
Brief Summary:
This is a prospective non-interventional study to evaluate impact of hospital pharmacist on drug management in patients only questionnaires with bronchopulmonary cancer treated by Chemotherapy andor Immunotherapy or Oral targeted therapy The primary objective of the study is to evaluate the number of unscheduled consultationshospitalizations during 6 months
Detailed Description:
Currently several treatments can be used for bronchopulmonary cancers targeted oral therapy OCT oral chemotherapy iv chemotherapy iv immunotherapy These therapies are rather unknown to community pharmacy and induce several adverse effects and drug interactions These treatments require collaboration between different professionals community and hospital pharmacists in order to allow follow up and security in patient supportive care
In our context of shortage of care staff with a polymedicated and elderly population we would like to assess the impact of hospital pharmacist in the drug management for patient with bronchopulmonary cancers treated by these therapies
Other French studies Lille Angers Tours involving hospital pharmacists were carried out and aimed to evaluate the number of pharmaceutical interventions carried out without assessing the impact on the patient In addition no study concerns the Center Val de Loire region
The aim of the study is to impact of hospital pharmacist interview on the number of unscheduled consultationshospitalizations
This is a prospective non-interventional study to evaluate impact of hospital pharmacist on drug management in patients with bronchopulmonary cancer Participants will be included after being informed and after obtaining no opposition to participate Data collection sheet will be performed by hospital pharmacist at inclusion Participants will be treated according to standard of care for cancer treatment An interview will be performed 1 month 3 months and 6 months after inclusion between hospital pharmacist and participant to obtain informations on cancer treatments questionnaires These interviews will be performed by phone or when the patient comes to the hospital for a follow-up consultation as part of the treatment of his cancer standard of care
A total of 60 participants will be included in this study based on 1 the number of patients received a novel cancer treatment in the center during 12 months and 2 considered eligibility criteria pharmacist availability and patients consent
In our context of shortage of care staff with a polymedicated and elderly population we would like to assess the impact of hospital pharmacist in the drug management for patient with bronchopulmonary cancers treated by these therapies
Other French studies Lille Angers Tours involving hospital pharmacists were carried out and aimed to evaluate the number of pharmaceutical interventions carried out without assessing the impact on the patient In addition no study concerns the Center Val de Loire region
The aim of the study is to impact of hospital pharmacist interview on the number of unscheduled consultationshospitalizations
This is a prospective non-interventional study to evaluate impact of hospital pharmacist on drug management in patients with bronchopulmonary cancer Participants will be included after being informed and after obtaining no opposition to participate Data collection sheet will be performed by hospital pharmacist at inclusion Participants will be treated according to standard of care for cancer treatment An interview will be performed 1 month 3 months and 6 months after inclusion between hospital pharmacist and participant to obtain informations on cancer treatments questionnaires These interviews will be performed by phone or when the patient comes to the hospital for a follow-up consultation as part of the treatment of his cancer standard of care
A total of 60 participants will be included in this study based on 1 the number of patients received a novel cancer treatment in the center during 12 months and 2 considered eligibility criteria pharmacist availability and patients consent
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None